vTv Therapeutics Inc. SG&A Expenses

SG&A Expenses of VTVT for past 10 years: annual, quarterly and twelve month trailing (TTM) including SG&A Expenses growth rates and interactive chart. Selling, general and administrative expense (SG&A) is reported on the income statement as the sum of all direct and indirect selling expenses and all general and administrative expenses (G&A) of a company. SG&A, also known as SGA, includes all the costs not directly tied to making a product or performing a service. That is, SG&A includes the costs to sell and deliver products and services and the costs to manage the company. It includes administrative


Highlights and Quick Summary

  • SG&A Expenses for the quarter ending September 29, 2020 was $1.07 Million (a -36.81% decrease compared to previous quarter)
  • Year-over-year quarterly SG&A Expenses decreased by -46.15%
  • Annual SG&A Expenses for 2019 was $8.54 Million (a -7.44% decrease from previous year)
  • Annual SG&A Expenses for 2018 was $9.22 Million (a -18.62% decrease from previous year)
  • Annual SG&A Expenses for 2017 was $11.3 Million (a 14.41% increase from previous year)
  • Twelve month SG&A Expenses ending September 29, 2020 was $7.21 Million (a -8.84% decrease compared to previous quarter)
  • Twelve month trailing SG&A Expenses decreased by -15.6% year-over-year
Trailing SG&A Expenses for the last four month:
29 Sep '20 29 Jun '20 30 Mar '20 30 Dec '19
$7.21 Million $7.9 Million $8.6 Million $8.54 Million
Visit stockrow.com/VTVT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical SG&A Expenses of vTv Therapeutics Inc.

Most recent SG&A Expensesof VTVT including historical data for past 10 years.

Interactive Chart of SG&A Expenses of vTv Therapeutics Inc.

vTv Therapeutics Inc. SG&A Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $1.07 $1.7 $2.45
2019 $1.99 $1.77 $2.39 $2.39 $8.54
2018 $2.07 $2.16 $2.74 $2.26 $9.22
2017 $2.94 $2.57 $3.01 $2.82 $11.33
2016 $2.25 $2.4 $2.67 $2.58 $9.91
2015 $2.37 $2.42 $2.3 $2.0 $9.08
2014 $1.59 $2.86 $11.72
2013 $11.38

Business Profile of vTv Therapeutics Inc.

Sector: Healthcare
Industry: Biotechnology
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation end products, which is in Phase II clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase II clinical trials to treat type 2 diabetes, as well as is in Phase II/III clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptidic agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing HPP737, HPP971, and HPP3033 for the treatment of chronic disease. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.